
Lerodalcibep, a novel PCSK9 inhibitor, reduced LDL cholesterol by over 50% in patients with or at high risk for cardiovascular disease, providing a more convenient and effective treatment option compared to existing therapies.


coremsg

Lerodalcibep, a third-generation PCSK9 inhibitor, reduced LDL by more than 50% vs placebo in patients with or at a high risk for CVD in the phase 3 LIBerate-HR trial.

Novel PCSK9 Inhibitor Reduced LDL by 50%

novel-pcsk9-inhibitor-lerodalcibep-demonstrated-significant-ldl-cholesterol-reduction-of-over-50-in-high-risk-cardiovascular-patients


Novel PCSK9 Inhibitor Lerodalcibep Demonstrated Significant LDL Cholesterol Reduction of Over 50% in High-Risk Cardiovascular Patients
